Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Srinath Sundararajan

Hematology Oncology | Hospital Medicine | Oncology
Texas Oncology
Texas Oncology PA
1331 W Grand Pkwy N, Suite 340, 
Katy, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Texas Oncology
Texas Oncology PA
1331 W Grand Pkwy N, Suite 340, 
Katy, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Srinath Sundararajan is a Hematologist Oncology specialist and a Hospital Medicine provider in Katy, Texas. Dr. Sundararajan is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and Wilms Tumor. Dr. Sundararajan is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Memorial Hermann Memorial City Hospital
Memorial Hermann Katy Hospital
Houston Methodist West Hospital
Columbus Community Hospital
Bellville Medical Center
Languages Spoken
English
Hindi
Spanish
Tamil
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
1331 W Grand Pkwy N, Suite 340, Katy, TX 77493
Call: 281-392-2757

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
Enrollment Status: Withdrawn
Publish Date: April 05, 2018
Intervention Type: Other, Drug, Biological
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

22 Total Publications

Clinical Manifestations and Treatment Outcomes of Metastatic Melanoma With Bone Marrow Infiltration.
Clinical Manifestations and Treatment Outcomes of Metastatic Melanoma With Bone Marrow Infiltration.
Journal: American journal of therapeutics
Published: June 06, 2023
View All 22 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Matthew T. Campbell
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Matthew T. Campbell
Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (23.0 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Campbell is a Hematologist and an Oncologist in Houston, Texas. Dr. Campbell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Amishi Y. Shah
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Amishi Y. Shah
Hematology Oncology | Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (23.6 miles away)
713-792-6127
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amishi Shah is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), and Familial Wilms Tumor 2.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Eric A. Jonasch
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Eric A. Jonasch
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (23.0 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jonasch is an Oncologist in Houston, Texas. Dr. Jonasch is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Hemangioblastoma, Chromophobe Renal Cell Carcinoma, Hypothalamic Hamartomas, and Nephrectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sundararajan's expertise for a condition
ConditionClose
    • Distinguished
    • Melanoma
      Dr. Sundararajan is
      Distinguished
      . Learn about Melanoma.
      See more Melanoma experts
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Sundararajan is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Sundararajan is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Sundararajan is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Wilms Tumor 2
      Dr. Sundararajan is
      Advanced
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    • Melanoma of the Eye
      Dr. Sundararajan is
      Advanced
      . Learn about Melanoma of the Eye.
      See more Melanoma of the Eye experts
    • Merkel Cell Carcinoma
      Dr. Sundararajan is
      Advanced
      . Learn about Merkel Cell Carcinoma.
      See more Merkel Cell Carcinoma experts
    View All 9 Advanced Conditions
    • Experienced
    • Acute Mountain Sickness
      Dr. Sundararajan is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Immune Thrombocytopenia
      Dr. Sundararajan is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Sundararajan is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Sundararajan is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Sundararajan is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Anaplastic Large Cell Lymphoma
      Dr. Sundararajan is
      Experienced
      . Learn about Anaplastic Large Cell Lymphoma.
      See more Anaplastic Large Cell Lymphoma experts
    View All 89 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved